GLPwatch

Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.

NCT07732738 · Recruiting

Last updated 2026-08-27

This study tests whether combining weight-loss surgery with a medication called GLP-1RA helps people with obesity lose more weight compared to surgery alone.

Status Recruiting Currently enrolling participants.
Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).
Type Interventional (clinical trial)
Design Non-randomized, open-label (no blinding) treatment study
Participants 400 people Planned (estimated).
Who can join Ages 16–70 · all sexes
Timeline Started 2025-01 · est. completion 2027-12
Where 7 sites · China

What this study is testing ClinicalTrials.gov NCT07732738 ↗

Description as written by the study sponsor.

Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration require attention. GLP-1 RAs offer distinct advantages for weight and metabolic improvement, and their combined application with surgery may yield synergistic benefits. Given the lack of multi-regional validation in China's diverse population, this multicenter study aims to confirm the real-world effectiveness and generalizability of bariatric surgery plus GLP-1RA across distinct regional cohorts.

Treatments tested

Main thing measuredthe Percentage of weight loss
SponsorChina-Japan Friendship Hospital
Conditions studiedObesity
GLP-1 drugs

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07732738 ↗